Experimental Tenofovir Vaginal Gel Stops HIV Infection

Major Finding: Women who applied a 1% tenofovir vaginal gel before and after sex had a significant 39% relative cut in HIV infection rate during 30 months of treatment, compared with placebo.

Data Source: CAPRISA 004, a randomized, placebo-controlled study of 843 women.

Disclosures: Dr. Karim said that he had no conflicts. Gilead, which supplied the tenofovir gel, licensed its use in Africa to CONRAD, a nongovernmental organization located in Arlington, Va.